Blonanserin patch vs. Other Antipsychotics for Acute Schizophrenia: A Systematic Review of Double-blind, Randomized, Placebo-controlled, Phase 3 Trials in Japan.

Abstract

INTRODUCTION:

The use of the blonanserin patch (BLO-P) for schizophrenia treatment was approved in Japan in 2019. This systematic review of trials in Japan assessed the efficacy and safety profile of BLO-P compared with other antipsychotics.

METHODS:

The systematic review included 6-week, double-blind, randomized, placebo-controlled, phase 3 trials in Japan that included patients with acute schizophrenia. Pooled data for patients receiving BLO-P 40 and 80 mg/day (BLO-P40+80) were compared with pooled data for patients receiving asenapine 10 and 20 mg/day (ASE10+20) and data for those receiving brexpiprazole 2 mg/day (BRE2) and paliperidone extended-release 6 mg/day (PAL-ER6).

RESULTS:

All the investigated treatments were superior to placebo in reducing the Positive and Negative Syndrome Scale (PANSS) total score; the Hedges' g values (95% confidence interval) for BLO-P40+80, ASE10+20, BRE2, and PAL-ER6 were-0.40 (-0.58,-0.22),-0.61 (-0.79,-0.42),-0.33 (-0.60,-0.07), and-0.69 (-0.93,-0.45), respectively. There were differences among the antipsychotics in the incidence of various individual adverse events.

DISCUSSION:

BLO-P40+80 may have a good efficacy/safety/tolerability profile for the treatment of patients with acute schizophrenia.

• Authors: Taro Kishi, Reiji Yoshimura, Yuki Matsuda, Kenji Sakuma, Nakao Iwata
• Journal: Pharmacopsychiatry (Pharmacopsychiatry) Vol. 53 Issue 3 Pg. 122-132 (Apr 2020) ISSN: 1439-0795 [Electronic] Germany
• PMID: 32000271 (Publication Type: Comparative Study, Journal Article, Systematic Review)
• Copyright: © Georg Thieme Verlag KG Stuttgart · New York.

Chemical References

• Antipsychotic Agents
• Piperazines
• Piperidines
• blonanserin

Topics

• Acute Disease
• Administration, Cutaneous
• Antipsychotic Agents (therapeutic use)
• Clinical Trials, Phase III as Topic
• Double-Blind Method
• Humans
• Japan
• Piperazines (therapeutic use)
• Piperidines (therapeutic use)
• Randomized Controlled Trials as Topic
• Schizophrenia (drug therapy)